Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | THRB | P10828 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | PLG | P00747 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.65 |
| ▸ | PAOX | Q6QHF9 | 4/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13772508 | 1.00 | LMNA (0.65) | LMNAKMT2ATHRBMEN1ALDH1A1 | |
| SCHEMBL727650 | 1.00 | LMNA (0.65) | LMNAKMT2ATHRBMEN1ALDH1A1 | |
| SCHEMBL2512531 | 1.00 | LMNA (0.65) | LMNAKMT2ATHRBMEN1ALDH1A1 | |
| SCHEMBL9423045 | 1.00 | LMNA (0.65) | LMNAKMT2ATHRBMEN1ALDH1A1 | |
| SCHEMBL728964 | 1.00 | LMNA (0.65) | LMNAKMT2ATHRBMEN1ALDH1A1 | |
| SCHEMBL2483428 | 1.00 | LMNA (0.65) | LMNAKMT2ATHRBMEN1ALDH1A1 | |
| SCHEMBL4964830 | 1.00 | LMNA (0.65) | LMNAKMT2ATHRBMEN1ALDH1A1 | |
| SCHEMBL601687 | 1.00 | LMNA (0.65) | LMNAKMT2ATHRBMEN1ALDH1A1 | |
| SCHEMBL16862574 | 1.00 | LMNA (0.65) | LMNAKMT2ATHRBMEN1ALDH1A1 | |
| SCHEMBL285471 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112334527-B | Foam particles based on long-chain polyamides | 巴斯夫欧洲公司 | 2023-05-16 | — | — | CN | claimed |
| EP-0772460-A1 | RADIOLABELED COMPOUNDS FOR THROMBUS IMAGING | DIATECH, INC. (US) | 1997-05-14 | — | — | EP | claimed |
| WO-1995033496-A1 | RADIOLABELED COMPOUNDS FOR THROMBUS IMAGING | DIATECH, INC. (US) | 1995-12-14 | — | — | WO | claimed |
| US-20260028651-A1 | METHOD OF PRODUCING & PROCESSING DIAMINES | AGAIN BIO APS (DK) | 2026-01-29 | — | — | US | disclosed |
| US-12503711-B2 | Method of producing and processing diamines to a diamine free base using a carbonate intermediate and an engineered microorganism | GENOMATICA, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20240182935-A1 | METHOD OF PRODUCING & PROCESSING DIAMINES | AGAIN BIO APS (DK) | 2024-06-06 | — | — | US | disclosed |
| US-11834690-B2 | Microorganisms and methods for the biosynthesis of adipate, hexamethylenediamine and 6-aminocaproic acid | GENOMATICA, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| EP-4273255-A2 | MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF HEXAMETHYLENEDIAMINE | Genomatica, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-11702682-B2 | Method of producing and processing diamines to a diamine free base using a carbonate intermediate and an engineered microorganism | GENOMATICA, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-3611254-B1 | MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF HEXAMETHYLENEDIAMINE | GENOMATICA INC (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-115721729-A | Compounds and methods for treating RNA mediated diseases | 阿拉基斯医疗公司 | 2023-03-03 | — | — | CN | disclosed |
| US-4889869-A | ANTIALDOSTERONISM AGENTS | CIBA-GEIGY CORPORATION (US) | 1989-12-26 | — | — | US | disclosed |
| EP-0320785-A2 | Peptides influencing the activity of the hypophysis of mammalians | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-06-21 | — | — | EP | disclosed |
| US-4758584-A | Antihypertensive 5-amino-4-hydroxyvaleryl derivatives substituted by sulphur-containing groups | CIBA-GEIGY CORPORATION (US) | 1988-07-19 | — | — | US | disclosed |
| US-4727060-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1988-02-23 | — | — | US | disclosed |
| US-4696932-A | ANTIALLERGENS, ANTIHISTAMINES, CARDIOTONIC AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1987-09-29 | — | — | US | disclosed |
| EP-0236734-A2 | 5-Amino-4-hydroxyvaleryl derivatives substituted by s-containing groups | CIBA-GEIGY AG (CH) | 1987-09-16 | — | — | EP | disclosed |
| US-4612315-A | Biologically-active 1,3-dipropyl-8-phenylxanthine derivatives | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1986-09-16 | — | — | US | disclosed |
| EP-0184550-A2 | 5-Amino-4-hydroxy valeryl amide derivatives | CIBA-GEIGY AG (CH) | 1986-06-11 | — | — | EP | disclosed |
| US-4165329-A | CARBOXYLATED UREA METAL SALTS | CHEVRON RESEARCH COMPANY (US) | 1979-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028651-A1 | METHOD OF PRODUCING & PROCESSING DIAMINES | DDC, DAO, ODC1 | LMNA 2536/4885KMT2A 1633/4885THRB 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.